Abstract
We recently observed a significantly increased risk for lung cancer in carriers of p53 germline mutations. Because cigarette smoking is known to play an important role in increasing the risk for lung cancer in the general population, we wanted to determine the role of cigarette smoking in lung cancer risk in people with a genetic susceptibility based on a p53 germline mutation. We studied 1263 people from 97 families enrolled in a cohort study of families systematically ascertained through childhood soft-tissue sarcoma patients treated at the M.D. Anderson Cancer Center, University of Texas, between 1944 and 1975. We assessed the incidence of lung and smoking-related cancers in 33 carriers of germline p53 mutations and in 1,230 noncarriers to determine whether there was an association between an inherited cancer predisposition, cigarette smoking, and cancer risk. We analyzed the association between cigarette smoking, mutation status, and lung and other smoking-related cancers by the Kaplan-Meier method and the Cox proportional hazards model with adjustments for birth year, race, and sex. In the hazards model, we incorporated a robust variance estimation to adjust for familial correlation. We observed an increased risk of a variety of histological types of lung cancer in the carriers of the p53 germline mutation. Mutation carriers who smoked had a 3.16-fold (95% confidence interval =1.48–6.78) higher risk for lung cancer than the mutation carriers who did not smoke. Our results demonstrate that cigarette smoking significantly increases lung cancer risk in carriers of a germline p53 mutation. This finding could be useful in designing strategies for early detection and treatment of lung and smoking-related cancers in individuals with this inherited cancer predisposition.
Similar content being viewed by others
References
Alberg AJ, Samet JM (2003) Epidemiology of lung cancer. Chest 123:21S-49S
Carbone D (1992) Smoking and cancer. Am J Med 93:13S-17S
Data Analysis Products Division (2000) S-PLUS 2000, User's guide; www.stats.ox.ac.uk
Doll R (1998) Uncovering the effects of smoking: historical perspective. Stat Methods Med Res 7:87–117
Evans SC, Mims B, McMasters KM, Foster CJ, deAndrade M, Amos CI, Strong LC, Lozano G (1998) Exclusion of a p53 germline mutation in a classic Li-Fraumeni syndrome family. Hum Genet 102:681–686
Flaman JM, Frebourg T, Moreau V, Charbonnier F, Martin C, Chappuis P, Sappino AP, Limacher IM, Bron L, Benhattar J (1995) A simple p53 functional assay for screening cell lines, blood, and tumors. Proc Natl Acad Sci USA 92:3963–3967
Hwang SJ, Lozano G, Amos CI, Strong LC (2003) Germline p53 Mutations in a cohort with childhood sarcoma: sex differences in cancer risk. Am J Hum Genet 72:975–983
Kleihues P, Schauble B, Zur HA, Esteve J, Ohgaki H (1997) Tumors associated with p53 germline mutations: a synopsis of 91 families. Am J Pathol 150:1–13
Kleinerman RA, Tarone RE, Abramson DH, Seddon JM, Li FP, Tucker MA (2000) Hereditary retinoblastoma and risk of lung cancer. J Natl Cancer Inst 92:2037–2039
Kondo K, Tsuzuki H, Sasa M, Sumitomo M, Uyama T, Monden Y (1996) A dose-response relationship between the frequency of p53 mutations and tobacco consumption in lung cancer patients. J Surg Oncol 61:20–26
Koop CE, Luoto J (1982) The health consequences of smoking: cancer. Overview of a report of the Surgeon General. Public Health Rep 97:318–324
Kure EH, Ryberg D, Hewer A, Phillips DH, Skaug V, Baera R, Haugen A (1996) p53 mutations in lung tumours: relationship to gender and lung DNA adduct levels. Carcinogenesis 17:2201–2205
Lavigueur A, Maltby V, Mock D, Rossant J, Pawson T, Bernstein A (1989) High incidence of lung, bone, and lymphoid tumors in transgenic mice overexpressing mutant alleles of the p53 oncogene. Mol Cell Biol 9:3982–3991
Lipsitz SR, Parzen M (1996) A jackknife estimator of variance for Cox regression for correlated survival data. Biometrics 52:291–298
Lustbader ED, Williams WR, Bondy ML, Strom S, Strong LC (1992) Segregation analysis of cancer in families of childhood soft-tissue-sarcoma patients. Am J Hum Genet 51:344–356
Lynch HT GH (1979) Childhood cancer and the SBLA syndrome. Med Hypotheses 5:15–22
Lynch HT, Radford B, Lynch JF (1990) SBLA syndrome revisited. Oncology 47:75–79
Malkin D, Li FP, Strong LC, Fraumeni JF Jr, Nelson CE, Kim DH, Kassel J, Gryka MA, Bischoff FZ, Tainsky MA (1990) Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250:1233–1238
Nichols KE, Malkin D, Garber JE, Fraumeni JF Jr, Li FP (2001) Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers. Cancer Epidemiol Biomarkers Prev 10:83–87
Ooi WL, Elston RC, Chen VW, Bailey-Wilson JE, Rothschild H (1986) Increased familial risk for lung cancer. J Natl Cancer Inst 76:217–222
SAS Institute (1994) SAS user's guide: statistics. SAS Institute, Cary, NC
Schwartz AG, Rothrock M, Yang P, Swanson GM (1999) Increased cancer risk among relatives of nonsmoking lung cancer cases. Genet Epidemiol 17:1–15
Srivastava S, Zou ZQ, Pirollo K, Blattner W, Chang EH (1990) Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature 348:747–749
Strong LC, Stine M, Norsted TL (1987) Cancer in survivors of childhood soft tissue sarcoma and their relatives. J Natl Cancer Inst 79:1213–1220
Strong LC, Williams WR, Tainsky MA (1992) The Li-Fraumeni syndrome: from clinical epidemiology to molecular genetics. Am J Epidemiol 135:190–199
Suzuki H, Takahashi T, Kuroishi T, Suyama M, Ariyoshi Y, Takahashi T, Ueda R (1992) p53 mutations in non-small cell lung cancer in Japan: association between mutations and smoking. Cancer Res 52:734–736
Varley JM, McGown G, Thorncroft M, Santibanez-Koref MF, Kelsey AM, Tricker KJ, Evans DG, Birch JM (1997) Germ-line mutations of TP53 in Li-Fraumeni families: an extended study of 39 families. Cancer Res 57:3245–3252
Wang SS, Samet JM (1997) Tobacco smoking and cancer: the promise of molecular epidemiology. Salud Publica Mex 39:331–345
Zang EA, Wynder EL (1992) Cumulative tar exposure. A new index for estimating lung cancer risk among cigarette smokers. Cancer 70:69–76
Zhang Z, Liu Q, Lantry LE, Wang Y, Kelloff GJ, Anderson MW, Wiseman RW, Lubet RA, You M (2000) A germ-line p53 mutation accelerates pulmonary tumorigenesis: p53-independent efficacy of chemopreventive agents green tea or dexamethasone/myo-inositol and chemotherapeutic agents taxol or adriamycin. Cancer Res 60:901–907
Acknowledgements
We thanks B. Mims for germline p53 testing, G. Nesom and V. Williams for editing, G. Robertson and D. Sembera for family contact, G. van der Ven for data collection, M.M. Ater for preliminary analysis, P. Begin for sample collection, and the family members for their kind support. This study was supported by grants from the National Institute of Health (CA 34936 and 5U01 CA 076293 04).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hwang, SJ., Cheng, L.SC., Lozano, G. et al. Lung cancer risk in germline p53 mutation carriers: association between an inherited cancer predisposition, cigarette smoking, and cancer risk. Hum Genet 113, 238–243 (2003). https://doi.org/10.1007/s00439-003-0968-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00439-003-0968-7